STOCK TITAN
  1. Home
  2. News
  3. LLY

Lilly(Eli) & Co - LLY STOCK NEWS

Welcome to our dedicated news page for Lilly(Eli) & Co (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly(Eli) & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lilly(Eli) & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lilly(Eli) & Co's position in the market.

News
Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA
Rhea-AI Summary
Eli Lilly and Company presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study, showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. The study demonstrated a 35% decline in participants with low-medium levels of tau and a 22% decline in all amyloid-positive early symptomatic AD participants. The treatment effect of donanemab continued to grow throughout the trial. FDA submission was completed in Q2, with regulatory action expected by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
clinical trial
-
News
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
Rhea-AI Summary
Medicxi (NYSE: LLY) announces the acquisition of its portfolio company, Versanis Bio, by Eli Lilly and Company for up to $1.925 billion USD in cash. Versanis is focused on developing new medicines for cardiometabolic diseases, with its lead asset, bimagrumab, currently being assessed in a Phase 2b study for the treatment of overweight or obesity. This acquisition reinforces Medicxi's commitment to investing in asset-driven companies and its belief in the therapeutic potential of bimagrumab in improving patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
acquisition
-
News
Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) to Acquire Versanis Bio, a Clinical-Stage Biopharmaceutical Company, for Development of New Medicines for Cardiometabolic Diseases. Lead asset is bimagrumab, a monoclonal antibody currently being assessed in the BELIEVE Phase 2b study alone and in combination with semaglutide in adults who are overweight or obese. Agreement includes potential $1.925 billion in cash for Versanis shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
acquisition
News
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC
Rhea-AI Summary
Eli Lilly and Company will host a webcast on July 17, 2023 at the Alzheimer's Association International Conference. The webcast will focus on results from the donanemab TRAILBLAZER-ALZ 2 clinical trial and the broader landscape in Alzheimer's disease. A live audio webcast will be available on Lilly's Investor website and a replay will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
none
-
News
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
clinical trial
-
News
New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
clinical trial
News
Lilly to Acquire Sigilon Therapeutics
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
acquisition
-
News
Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight
Rhea-AI Summary
Eli Lilly and Company announced phase 2 data for retatrutide, their investigational molecule for the treatment of obesity. The primary endpoint was met with a mean weight reduction of up to 17.5% at 24 weeks. In a secondary endpoint, retatrutide demonstrated a mean weight reduction of up to 24.2% at 48 weeks. The safety profile was similar to other therapies, with gastrointestinal side effects being the most commonly reported. The results were presented at the American Diabetes Association's 83rd Scientific Sessions and published in The New England Journal of Medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
clinical trial
-
News
Lilly Declares Third-Quarter 2023 Dividend
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
dividends
News
Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock LLY logo
Lilly(Eli) & Co

NYSE:LLY

LLY Rankings

#10 Ranked by Market Cap
#348 Ranked by Stock Gains
#1933 Ranked by Dividends

LLY Stock Data

714.63B
897.86M
0.16%
84.31%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Indianapolis

About LLY

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.